Prosecution Insights
Last updated: November 05, 2026
Application No. 18/367,908

TISSUE OCCLUDING AGENT COMPRISING AN IEIKIEIKIEIKI PEPTIDE

Final Rejection §103§DOUBLEPATENT
Filed
Sep 13, 2023
Priority
Oct 06, 2008 — JP 2008-259860 +7 more
Examiner
REYNOLDS, FRED H
Art Unit
1658
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
3-D Matrix Ltd.
OA Round
2 (Final)
33%
Grant Probability
At Risk
3-4
OA Rounds
0m
Est. Remaining
73%
With Interview

Examiner Intelligence

Grants only 33% of cases
33%
Career Allowance Rate
283 granted / 852 resolved
-26.8% vs TC avg
Strong +40% interview lift
Without
With
+39.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
92 currently pending
Career history
954
Total Applications
across all art units

Statute-Specific Performance

§101
5.1%
-34.9% vs TC avg
§103
30.2%
-9.8% vs TC avg
§102
14.0%
-26.0% vs TC avg
§112
28.6%
-11.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 852 resolved cases

Office Action

§103 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Withdrawn Objections The objection to the title due to naming a sequence unrelated to the claims is hereby withdrawn due to amendment. Election/Restrictions Applicants elected group II (method of stopping bleeding) using SEQ ID 3 in 1-3% aqueous solution for endoscopic demucosation without traverse in the reply filed on 30 March, 2026. In the response of 18 Aug, 2026, applicants amended the claims so they no longer read on their elected species. Claims Status Claims 16-23, 30-32, and 34-36 are pending. Claims 30-32 have been amended. Claims 16-23 have been withdrawn from consideration due to an election/restriction requirement. Withdrawn Rejections The rejection of claims 30-32 and 34-36 under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Yamamoto (US 6,319,260) in view of Ellis-Behnke et al (Nanomed. (2006) 2(4) p207-215, cited by applicants) and Gelain et al (Macromol. Biosci. (2007) 7 p544-551, cited by applicants) is hereby withdrawn due to amendment. The rejection of claims 30-32 and 34-36 on the ground of nonstatutory double patenting as being unpatentable over claims 1, 2, 16 and 17 of U.S. Patent No. 11,801,281 is hereby withdrawn due to amendment. Maintained/Modified Rejections Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 30-32 and 34-36 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 3, 9, and 12 of copending Application No. 19/337,620 (US 20260083917) in view of Yamamoto (US 6,319,260). Competing claims 1 and 3 describe a formulation that can comprise SEQ ID 1, identical with SEQ ID 1 of the examined claims. Competing claim 9 describes treating a wound in a mucous membrane to help it heal, comprising administering the formulation of competing claim 3, while competing claim 12 requires endoscopy to apply the material. The difference between the competing claims and the examined claims is that the competing claims do not discuss endoscopic demucosation, or lifting the site for excision. Yamamoto discusses endoscopic mucosal resection (title). Prior systems use saline injected in the submucosal layer to lift the mucosal section, which is trapped by a snare and excised. However, the saline rapidly diffuses, leading to disappearance of the protrusion to be excised (column 1, line 40-54). An alternative adds epinephrine to the saline to prevent or minimize bleeding (column 1, line 55-58), which deals with that common complication (column 1, line 44-47). However, the material is emitted from the opening caused by excising the tissue, which causes the protrusion to disappear (column 1, line 65-column 2, line 3). To overcome this issue, a mucopolysaccharide solution is used, as it diffuses slowly and is too viscous to bleed out of an incision quickly (column 2, line 42-49). It is also used with a hemostatic or angiotonic material (column 2, line 25-26). The amount of the hemostatic or angiotonic material varies depending on what it is (column 3, line 56-60). Therefore, it would be obvious to add the formulation of the competing claims to the formulation of Yamamoto, to help the wound to heal, as described in the competing claims. As both deal with wounds to the mucous surface, an artisan in this field would attempt this modification with a reasonable expectation of success. This is a provisional nonstatutory double patenting rejection. response to applicant’s arguments Applicants request that this rejection be held in abeyance until any claim is found allowable. However, until this rejection is overcome, it will remain valid. New Rejections Claim Rejections - 35 USC § 103 The following is a quotation of pre-AIA 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action: (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under pre-AIA 35 U.S.C. 103(a) are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims under pre-AIA 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of pre-AIA 35 U.S.C. 103(c) and potential pre-AIA 35 U.S.C. 102(e), (f) or (g) prior art under pre-AIA 35 U.S.C. 103(a). Claims 30-32 and 34-36 are rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Yamamoto (US 6,319,260) in view of Ellis-Behnke et al (Nanomed. (2006) 2(4) p207-215, cited by applicants) and Gelain et al (Macromol. Biosci. (2007) 7 p544-551, cited by applicants). Yamamoto discusses endoscopic mucosal resection (title). Prior systems use saline injected in the submucosal layer to lift the mucosal section, which is trapped by a snare and excised. However, the saline rapidly diffuses, leading to disappearance of the protrusion to be excised (column 1, line 40-54). An alternative adds epinephrine to the saline to prevent or minimize bleeding (column 1, line 55-58), which deals with that common complication (column 1, line 44-47). However, the material is emitted from the opening caused by excising the tissue, which causes the protrusion to disappear (column 1, line 65-column 2, line 3). To overcome this issue, a mucopolysaccharide solution is used, as it diffuses slowly and is too viscous to bleed out of an incision quickly (column 2, line 42-49). It is also used with a hemostatic or angiotonic material (column 2, line 25-26). The amount of the hemostatic or angiotonic material varies depending on what it is (column 3, line 56-60). The difference between this reference and the examined claims is that this reference does not discuss SEQ ID 1. Ellis-Behnke et al discuss nano-hemostat solutions (title). Self assembling peptides form a barrier that achieves hemostasis immediately when applied to a wound in a number of different bleeding scenarios, including such difficult situations as femoral arterial bleeding and liver injury (abstract). The self assembling peptide used was RADA16-1 (4th page, 1st paragraph), which as evidenced by applicant’s disclosure (paragraph 37) is identical with SEQ ID 1 of the examined claims, dissolved 1-4% (w/v) in water (4th page, 2nd column, 1st paragraph). All concentrations were effective, but higher concentrations worked more rapidly (7th page, 2nd column, 3d paragraph). The proposed mechanism of action is that the material forms a barrier (8th page, 1st column, 4th paragraph). This reference discusses using RADA16-1 for its hemostatic effects. Therefore, it would be obvious to use the peptide of Ellis-Behnke et al in the therapy of Yamamoto, as Ellis-Behnke et al teach that it will stop bleeding, which Yamamoto states is a common complication of the procedure. As Ellis-Behnke et al show that it will work in two different bleeding models, an artisan in this field would use this sequence with a reasonable expectation of success. Ellis-Behnke et al render obvious using SEQ ID 1 in the endoscopic demucosation of Yamamoto, rendering obvious claims 30-32. Ellis-Behnke et al use 1-4% w/v solutions of the peptide, overlapping with the ranges of claims 34-36, rendering them obvious. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to FRED REYNOLDS whose telephone number is (571)270-7214. The examiner can normally be reached M-Th 9-3:30. Examiner interviews are available via telephone and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melissa Fisher can be reached at 571-270-7430. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /FRED H REYNOLDS/Primary Examiner, Art Unit 1658
Read full office action

Prosecution Timeline

Sep 13, 2023
Application Filed
May 07, 2026
Non-Final Rejection mailed — §103, §DOUBLEPATENT
Aug 18, 2026
Response Filed
Sep 23, 2026
Final Rejection mailed — §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12766182
TOPICAL CYCLOSPORINE-CONTAINING FORMULATIONS AND USES THEREOF
2y 7m to grant Granted Oct 20, 2026
Patent 12760079
CNP Variants and Conjugates Thereof
4y 7m to grant Granted Oct 13, 2026
Patent 12753208
ANTIVIRAL STRUCTURALLY-STABILIZED EBOLAVIRUS PEPTIDES AND USES THEREOF
3y 5m to grant Granted Oct 06, 2026
Patent 12753222
POLYMERIC FORMS OF H-NOX PROTEINS
2y 5m to grant Granted Oct 06, 2026
Patent 12734210
PEPTIDE HAVING HAIR LOSS PREVENTION OR HAIR GROWTH PROMOTION ACTIVITY AND USE THEREOF
2y 5m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
33%
Grant Probability
73%
With Interview (+39.7%)
3y 0m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 852 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month